L. Roy Papp & Associates LLP Raises Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

L. Roy Papp & Associates LLP boosted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 31.9% during the fourth quarter, HoldingsChannel reports. The firm owned 620 shares of the company’s stock after buying an additional 150 shares during the period. L. Roy Papp & Associates LLP’s holdings in IDEXX Laboratories were worth $256,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of IDXX. FSA Wealth Management LLC purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. increased its stake in IDEXX Laboratories by 5,700.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock valued at $29,000 after acquiring an additional 57 shares during the last quarter. Mowery & Schoenfeld Wealth Management LLC raised its position in IDEXX Laboratories by 750.0% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock valued at $34,000 after purchasing an additional 60 shares in the last quarter. Ashton Thomas Securities LLC bought a new stake in IDEXX Laboratories during the third quarter worth about $37,000. Finally, Retirement Wealth Solutions LLC purchased a new position in shares of IDEXX Laboratories in the 4th quarter worth about $31,000. 87.84% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 13,330 shares of company stock valued at $6,161,276 over the last ninety days. 2.11% of the stock is owned by insiders.

IDEXX Laboratories Price Performance

IDXX stock opened at $463.74 on Wednesday. The stock has a market capitalization of $37.98 billion, a price-to-earnings ratio of 43.46, a PEG ratio of 3.47 and a beta of 1.37. The firm’s 50-day moving average price is $429.03 and its two-hundred day moving average price is $453.28. The company has a current ratio of 1.31, a quick ratio of 1.03 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $583.39.

Analysts Set New Price Targets

A number of brokerages recently weighed in on IDXX. Morgan Stanley decreased their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Leerink Partners assumed coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They set an “outperform” rating and a $500.00 price target on the stock. Piper Sandler upped their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research note on Monday. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Bank of America boosted their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $533.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.